Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib?

Neuro-oncology - 2 Nov 2023

Preusser Matthias, Geurts Marjolein, Hainfellner Johannes A, van den Bent Martin J

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Central Nervous System
Share to Glioma
Share to Isocitrate Dehydrogenase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to World Health Organization

Source

Open in PubMed Open full text

Identifiers

PMID: 37477610
DOI: 10.1093/neuonc/noad113
PMCID: PMC10628922

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib?PMID 37477610Read ↗

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.Semantic proximity Read ↗

Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?Semantic proximity Read ↗

State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond.Semantic proximity Read ↗

Management of Adult Patients With Isocitrate Dehydrogenase-Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro-Oncology.Semantic proximity Read ↗

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.Semantic proximity Read ↗

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaSemantic proximity Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas.Semantic proximity Read ↗

Vorasidenib: First Approval.Semantic proximity Read ↗

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical IndicationsSemantic proximity Read ↗

Journal of Neuro Oncology: Diagnostic and therapeutic implications of IDH mutations in gliomas following the 2021 World Health Organization classification of CNS tumors.Semantic proximity Read ↗

Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics DevelopmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.